Novo Nordisk’s Amycretin Shows Promising Weight Loss in Early Trials
Novo Nordisk’s new injectable weight-loss drug, amycretin, shows promise in early trials, achieving up to 22% weight reduction. This positive development follows previous setbacks and boosts hopes for a new leading obesity treatment.
Novo Nordisk’s Amycretin Shows Promising Weight Loss in Early Trials Read More »